XML 16 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Organization
 9 Months Ended
Sep. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Organization

1. Organization

Description of the Business

RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. In May 2019, the Company changed its name from FLX Bio, Inc. to RAPT Therapeutics, Inc.

The Company is located in South San Francisco, California.

Equity Financing

In February 2020, the Company completed an underwritten public offering (the “Follow‑on Offering”) of 2,500,000 shares of common stock at an offering price of $30.00 per share. The Company received approximately $69.8 million in net proceeds from the Follow-on Offering, after deducting underwriting discounts and other offering-related costs.